10. Oppfølging

Aziz, N. M. (2007). Cancer survivorship research: state of knowledge, challenges and opportunities. Acta oncologica (Stockholm, Sweden), 46(4), 417-32.

Borhan, A., Reeder, J. E., O'Connell, M. J., Wright, K. O., Wheeless, L. L., di Sant'Agnese, P. A., ... Messing, E. M. (2003). Grade progression and regression in recurrent urothelial cancer. The Journal of urology, 169(6), 2106-9.

Cancer i urinblåsa, njurbäcken, urin-ledare och urinrör: nationellt vårdprogram (2015). (rev. utg.) Lund: Regionala cancercentrum i Samverkan. Hentet fra http://www.cancercentrum.se/globalassets/cancerdiagnoser/urinvagar/urinblase--och-urinrorscancer/vardprogram/natvp_cancer_urinvagar_25aug15.pdf

Choe, J., Braschi-Amirfarzan, M., Tirumani, S. H., Shinagare, A. B., Kim, K. W., Ramaiya, N. H., & Krajewski, K. M. (2017). Updates for the radiologist in non-muscle-invasive, muscle-invasive, and metastatic bladder cancer. Abdominal radiology (New York), 42(11), 2710-2724.

EAU (2022). EAU Guidelines. Edition presented at the EAU Annual Congress Amsterdam Arnhem: European Association of Urology.

Efstathiou, J. A., Bae, K., Shipley, W. U., Kaufman, D. S., Hagan, M. P., Heney, N. M., & Sandler, H. M. (2009). Late Pelvic Toxicity After Bladder-Sparing Therapy in Patients With Invasive Bladder Cancer: RTOG 89-03, 95-06, 97-06, 99-06. Journal of Clinical Oncology, 27(25), 4055-4061.

Fujii, Y., Kawakami, S., Koga, F., Nemoto, T., & Kihara, K. (2003). Long-term outcome of bladder papillary urothelial neoplasms of low malignant potential. BJU international, 92(6), 559-62.

Fung, C., Fossa, S. D., Milano, M. T., Oldenburg, J., & Travis, L. B. (2013). Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. Journal of Clinical Oncology, 31(30), 3807-14.

Gofrit, O. N., Pode, D., Lazar, A., Katz, R., & Shapiro, A. (2006). Watchful waiting policy in recurrent Ta G1 bladder tumors. European urology, 49(2), 303-6; discussion 306-7.

Gogna, N. K., Matthews, J. H., Turner, S. L., Mameghan, H., Duchesne, G. M., Spry, N., ... Trans Tasman Radiation Oncology, G. (2006). Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 81(1), 9-17.

Haugnes, H. S., Bosl, G. J., Boer, H., Gietema, J. A., Brydoy, M., Oldenburg, J., ... Fossa, S. D. (2012). Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. Journal of Clinical Oncology, 30(30), 3752-3763.

Herman, J. M., Smith, D. C., Montie, J., Hayman, J. A., Sullivan, M. A., Kent, E., ... Sandler, H. M. (2004). Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy. Urology, 64(1), 69-73.

Herr, H. W., Cookson, M. S., & Soloway, S. M. (1996). Upper tract tumors in patients with primary bladder cancer followed for 15 years. The Journal of urology, 156(4), 1286-7.

Holmang, S., Andius, P., Hedelin, H., Wester, K., Busch, C., & Johansson, S. L. (2001). Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. The Journal of urology, 165(4), 1124-8; discussion 1128-30.

Holmang, S., & Johansson, S. L. (2002). Stage Ta-T1 bladder cancer: The relationship between findings at first followup cystoscopy and subsequent recurrence and progression. The Journal of urology, 167(4), 1634-1637.

Hurle, R., Losa, A., Manzetti, A., & Lembo, A. (1999). Upper urinary tract tumors developing after treatment of superficial bladder cancer: 7-year follow-up of 591 consecutive patients. Urology, 53(6), 1144-1148.

Ito, A., Shintaku, I., Satoh, M., Ioritani, N., Aizawa, M., Tochigi, T., ... Arai, Y. (2013). Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. Journal of Clinical Oncology, 31(11), 1422-7.

Lagrange, J. L., Bascoul-Mollevi, C., Geoffrois, L., Beckendorf, V., Ferrero, J. M., Joly, F., ... Study Group on Genito-Urinary, T. (2011). Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015). International journal of radiation oncology, biology, physics, 79(1), 172-8.

Leblanc, B., Duclos, A. J., Benard, F., Cote, J., Valiquette, L., Paquin, J. M., ... Perreault, J. P. (1999). Long-term followup of initial Ta grade 1 transitional cell carcinoma of the bladder. The Journal of urology, 162(6), 1946-50.

Majewski, W., & Tarnawski, R. (2009). Acute and late toxicity in radical radiotherapy for bladder cancer. Clinical oncology, 21(8), 598-609.

Mangar, S. A., Foo, K., Norman, A., Khoo, V., Shahidi, M., Dearnaley, D. P., ... Huddart, R. A. (2006). Evaluating the effect of reducing the high-dose volume on the toxicity of radiotherapy in the treatment of bladder cancer. Clinical oncology, 18(6), 466-73.

Mariappan, P., & Smith, G. (2005). A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. The Journal of urology, 173(4), 1108-1111.

O'Brien, T., Ray, E., Singh, R., Coker, B., & Beard, R. (2011). Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). European urology, 60(4), 703-10.

Oge, O., Erdem, E., Atsu, N., ahin, A., & Ozen, H. (2000). Proposal for changes in cystoscopic follow-up of patients with low-grade pTa bladder tumor. European urology, 37(3), 271-4.

Ploussard, G., Daneshmand, S., Efstathiou, J. A., Herr, H. W., James, N. D., Rodel, C. M., ... Kassouf, W. (2014). Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review. European urology, 66(1), 120-137.

Pruthi, R. S., Baldwin, N., Bhalani, V., & Wallen, E. M. (2008). Conservative management of low risk superficial bladder tumors. The Journal of urology, 179(1), 87-90; discussion 90.

Shipley, W. U., Kaufman, D. S., Zehr, E., Heney, N. M., Lane, S. C., Thakral, H. K., ... Zietman, A. L. (2002). Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology, 60(1), 62-7; discussion 67-8.

Soloway, M. S., Bruck, D. S., & Kim, S. S. (2003). Expectant management of small, recurrent, noninvasive papillary bladder tumors. The Journal of urology, 170(2 Pt 1), 438-41.

Solsona, E., Iborra, I., Dumont, R., Rubio-Briones, J., Casanova, J., & Almenar, S. (2000). The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. The Journal of urology, 164(3), 685-689.

Sylvester, R. J., van der Meijden, A. P., Oosterlinck, W., Witjes, J. A., Bouffioux, C., Denis, L., ... Kurth, K. (2006). Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. European urology, 49(3), 466-5; discussion 475-7.

Søndergaard, J., Holmberg, M., Jakobsen, A. R., Agerbæk, M., Muren, L. P., & Høyer, M. (2014). A comparison of morbidity following conformal versus intensity-modulated radiotherapy for urinary bladder cancer. Acta oncologica (Stockholm, Sweden), 53(10), 1321-8.

Weiss, C., Engehausen, D. G., Krause, F. S., Papadopoulos, T., Dunst, J., Sauer, R., & Rodel, C. (2007). Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. International journal of radiation oncology, biology, physics, 68(4), 1072-80.

Zieger, K., Wolf, H., Olsen, P. R., & Hojgaard, K. (2000). Long-term follow-up of noninvasive bladder tumours (stage Ta): recurrence and progression. BJU international, 85(7), 824-8.